Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Amantadine Sulfate

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    New Data Analysis Supports GOCOVRI for Motor Complications for People With PD
    New Data Analysis Supports GOCOVRI for Motor Complications for People With PD

    10 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210610005080/en

    BUSINESSWIRE
    10 Jun 2021
    Share Share
    Adamas' Parkinson's drug gets US marketing authorisation for second indication
    Adamas' Parkinson's drug gets US marketing authorisation for second indication

    01 Feb 2021

    // PHARMAFILE

    http://www.pharmafile.com/news/570439/adamas-parkinsons-drug-gets-us-marketing-authorisation-second-indication

    PHARMAFILE
    01 Feb 2021
    Share Share
    Adamas announces issuance of new U.S. patent for GOCOVRI
    Adamas announces issuance of new U.S. patent for GOCOVRI

    13 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/13/2032747/0/en/Adamas-announces-issuance-of-new-U-S-patent-for-GOCOVRI-in-Parkinson-s-disease-expands-coverage-with-reduction-of-OFF-time-and-increased-good-ON-time.html

    GLOBENEWSWIRE
    13 May 2020
    Share Share
    Gocovri™ (Amantadine) : Adamas Pharma, v. Sandoz
    Gocovri™ (Amantadine) : Adamas Pharma, v. Sandoz

    10 May 2018

    // PATENT LITIGATION

    https://www.pharmacompass.com/pdf/news/gocovri-amantadine-adamas-pharma-v-sandoz-1526283687.pdf

    PATENT LITIGATION
    10 May 2018
    Share Share